There was a higher risk of neutropenia (9 studies) for patients treated with Il-6 (receptor) antagonists compared to patients not treated with IL-6 (receptor) antagonists: RR 7.3 (95% CI 2.6 to 20) see Fig. S6. This evidence concerns the gene IL6 and neutropenia.